The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
14-gene immunoglobulin (IGG) and proliferation signatures and association with overall survival across cancer-types.
 
Francesco Schettini
No Relationships to Disclose
 
Laia Paré
Employment - Reveal Genomics
 
Mercedes Marín-Aguilera
Employment - Reveal Genomics
 
Susana Puig
No Relationships to Disclose
 
Laura Mezquita
No Relationships to Disclose
 
Neus Baste
Consulting or Advisory Role - Amgen; Bayer; BioNTech; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; ISA Pharmaceuticals; Merck Serono; Merck Serono; MSD Oncology; Novartis; Roche; Roche
Research Funding - Merck Serono
 
Tomás Pascual
No Relationships to Disclose
 
Olga Martinez Saez
Consulting or Advisory Role - Roche
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Pfizer
 
Benedetta Conte
No Relationships to Disclose
 
Pedro Jares
No Relationships to Disclose
 
Joan Anton Puig-Butillé
No Relationships to Disclose
 
Esther Sanfeliu Torres
No Relationships to Disclose
 
Blanca González-Farre
No Relationships to Disclose
 
Patricia Villagrasa
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - NanoString Technologies
 
Pier Franco Conte
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Gilead Sciences; Reveal Genomics
Speakers' Bureau - AstraZeneca; BMS; Lilly; Novartis; Roche/Genentech; Tesaro
Research Funding - BMS (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2Dx patent
Expert Testimony - AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Pfizer
 
Charles Perou
Stock and Other Ownership Interests - Bioclassifier; Reveal Genomics
Consulting or Advisory Role - Bioclassifier; Reveal Genomics
 
Joel S. Parker
Stock and Other Ownership Interests - GeneCentric; Reveal Genomics
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
Patents, Royalties, Other Intellectual Property - Joel Parker has authored patents related to the PAM50 algorithm which are licensed to Nanostring Technologies.
 
Fara Brasó Maristany
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc